Douglas R Galasko
Overview
Explore the profile of Douglas R Galasko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
9706
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sheth U, Oijerstedt L, Heckman M, White L, Heuer H, Lario Lago A, et al.
Mol Neurodegener
. 2025 Mar;
20(1):30.
PMID: 40075459
Background: Therapeutic development for frontotemporal dementia (FTD) is hindered by the lack of biomarkers that inform susceptibility/risk, prognosis, and the underlying causative pathology. Blood glial fibrillary acidic protein (GFAP) has...
2.
Bateman R, Li Y, McDade E, Llibre-Guerra J, Clifford D, Atri A, et al.
medRxiv
. 2025 Feb;
PMID: 39974075
Background: Amyloid-plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, the potential for delaying the onset of clinical symptoms in asymptomatic people is unknown. The...
3.
Valdes P, Caldwell A, Liu Q, Fitzgerald M, Ramachandran S, Karch C, et al.
Alzheimers Res Ther
. 2025 Jan;
17(1):5.
PMID: 39754192
Background: PSEN1, PSEN2, and APP mutations cause Alzheimer's disease (AD) with an early age at onset (AAO) and progressive cognitive decline. PSEN1 mutations are more common and generally have an...
4.
Vargas-Gonzalez J, Dimal N, Cortez K, Heuer H, Forsberg L, Appleby B, et al.
Alzheimers Dement
. 2024 Dec;
21(2):e14448.
PMID: 39713899
Introduction: Psychotropic medication (PM) use in behavioral-variant frontotemporal dementia (bvFTD) is higher than in other dementias. However, no information exists on whether PM use differs between sporadic and genetic bvFTD....
5.
VandeBunte A, Lee H, Paolillo E, Hsiung G, Staffaroni A, Saloner R, et al.
Alzheimers Dement
. 2024 Sep;
20(10):6820-6833.
PMID: 39240048
Introduction: Cardiovascular health is important for brain aging, yet its role in the clinical manifestation of autosomal dominant or atypical forms of dementia has not been fully elucidated. We examined...
6.
Vandebergh M, Ramos E, Corriveau-Lecavalier N, Ramanan V, Kornak J, Mester C, et al.
medRxiv
. 2024 Apr;
PMID: 38633784
Background And Objectives: has been proposed as a modifier of disease risk in FTLD-TDP, particularly in mutation carriers. Furthermore, has been investigated as a disease modifier in the context of...
7.
Sandau U, Wiedrick J, McFarland T, Galasko D, Fanning Z, Quinn J, et al.
Sci Rep
. 2024 Jan;
14(1):2148.
PMID: 38272952
There is great interest in developing clinical biomarker assays that can aid in non-invasive diagnosis and/or monitoring of human diseases, such as cancer, cardiovascular disease, and neurological diseases. Yet little...
8.
Valdes P, Henry K, Fitzgerald M, Muralidharan K, Caldwell A, Ramachandran S, et al.
Mol Brain
. 2023 Nov;
16(1):75.
PMID: 37924159
Non-familial Alzheimer's disease (AD) occurring before 65 years of age is commonly referred to as early-onset Alzheimer's disease (EOAD) and constitutes ~ 5-6% of all AD cases (Mendez et al....
9.
Jain L, Khrestian M, Formica S, Tuason E, Pillai J, Rao S, et al.
Alzheimers Dement
. 2023 Sep;
20(1):549-562.
PMID: 37740924
Introduction: The National Institute on Aging - Alzheimer's Association (NIA-AA) ATN research framework proposes to use biomarkers for amyloid (A), tau (T), and neurodegeneration (N) to stage individuals with AD...
10.
Rajabli F, Benchek P, Tosto G, Kushch N, Sha J, Bazemore K, et al.
medRxiv
. 2023 Jul;
PMID: 37461624
Limited ancestral diversity has impaired our ability to detect risk variants more prevalent in non-European ancestry groups in genome-wide association studies (GWAS). We constructed and analyzed a multi-ancestry GWAS dataset...